文献速递炎症性肠病消化道肿瘤与早癌

药物微生物组学:肠道微生物组在免疫调节与癌症治疗中的作用

Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy.
PubMed 文献 · Gastroenterology · 2025-05-15

个体对同一药物的治疗反应和不良事件存在高度异质性,肠道微生物组是其中关键因素。药物微生物组学研究微生物组变异与药物反应及处置的相互作用,这种作用复杂且双向。本文综述药物与肠道微生物组相互作用的最新研究,聚焦癌症免疫治疗及炎症性肠病和实体器官移植中的免疫调节,并探讨粪菌移植增强免疫检查点阻断疗效的临床试验证据。

要点

  • 肠道微生物组被视为第二基因组,具有显著代谢能力,影响药物反应与不良事件。
  • 微生物与药物相互作用双向:药物可改变微生物生长或肠道微生物组组成与功能。
  • 肠道微生物组通过酶活性直接、或经宿主介导的免疫与代谢机制间接调节药物反应。

核心结论

  • 多项证据表明肠道微生物组与药物相互作用并影响疗效与安全性,但需设计良好的临床研究及体内外整合模型以获得一致结果、改善临床转化并进一步释放肠道微生物组改善药物反应的潜力。

研究设计与样本

  • 综述性文章,总结近期关于药物与肠道微生物组相互作用的研究,聚焦癌症免疫治疗及炎症性肠病和实体器官移植中的免疫调节。

主要发现

  • 个体对同一药物的治疗反应和不良事件存在高度异质性,肠道微生物组是日益被认识到的重要 contributing 因素。
  • 肠道微生物组被视为第二基因组,具有显著代谢能力,药物微生物组学作为药物基因组学的自然延伸而出现。
  • 微生物与药物之间的相互作用复杂且双向:药物可直接改变微生物生长或影响肠道微生物组组成与功能。
  • 肠道微生物组可通过酶活性直接调节药物反应,也可通过宿主介导的免疫和代谢机制间接调节。
  • 近期临床试验强调粪菌移植作为增强免疫检查点阻断疗效的策略。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要设计良好的临床研究以及体内和体外整合模型来获得一致结果、改善临床转化并进一步释放肠道微生物组改善药物反应的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a large heterogeneity among individuals in their therapeutic responses to the same drug and in the occurrence of adverse events. A key factor increasingly recognized to contribute to this variability is the gut microbiome. The gut microbiome can be regarded as a second genome, holding significant metabolic capacity. Consequently, the field of pharmacomicrobiomics has emerged as a natural extension of pharmacogenomics for studying variations in drug responses. Pharmacomicrobiomics explores the interaction of microbiome variation with drug response and disposition. The interaction between microbes and drugs is, however, complex and bidirectional. While drugs can directly alter microbial growth or influence gut microbiome composition and functionality, the gut microbiome also modulates drug responses directly through enzymatic activities and indirectly via host-mediated immune and metabolic mechanisms. Here we review recent studies that demonstrate the interaction between drugs and the gut microbiome, focusing on cancer immunotherapy and immunomodulation in the context of inflammatory bowel disease and solid organ transplantation. Because the gut microbiome is modifiable, pharmacomicrobiomics presents promising opportunities for optimizing therapeutic outcomes, with recent clinical trials highlighting fecal microbiota transplantation as a strategy to enhance the efficacy of immune checkpoint blockade. We also shed light on the future perspectives for patients arising from this field. Although multiple lines of evidence already demonstrate that the gut microbiome interacts with drugs, and vice versa, thereby affecting treatment efficacy and safety, well-designed clinical studies and integrated in vivo and ex vivo models are necessary to obtain consistent results, improve clinical translation, and further unlock the gut microbiome's potential to improve drug responses.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Bolte LA, Björk JR, Gacesa R, et al. Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy. Gastroenterology. 2025. PMID: 40381958. doi:10.1053/j.gastro.2025.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。